Sfoglia per AUTORE
CAMARDA F
Collezione ASL Biella

  

Items : 2

45TiP A randomized, molecular driven phase II trial of carboplatin-paclitaxel-bev vs carboplatin-paclitaxel-bev-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer in Annals of Oncology

2022
ASL Biella

Carbone MV; Giudice E; Camarda F; Nero C; Tronconi F; Lorusso D; Ghizzoni V; Ricci C; Mosconi AM; Cormio G; Valabrega G; Zavallone L; Pignata S; Siena S; Scambia G; Salutari V; Musacchio L;

MITO 25.1: A RANDOMIZED, MOLECULAR DRIVEN PHASE II TRIAL OF CARBOPLATIN-PACLITAXELBEVACIZUMAB VS CARBOPLATIN-PACLITAXELBEVACIZUMAB- RUCAPARIB VS CARBOPLATINPACLITAXEL- RUCAPARIB, SELECTED ACCORDING TO HRD STATUS, IN PATIENTS WITH ADVANCED OVARIAN CANCER in International Journal of Gynecological Cancer

2022
ASL Città di Torino
ASL Biella

Musacchio L; Salutari V; Pignata S; Valabrega G; Zavallone L; Cormio G; Mosconi AM; Giolitto S; Camarda F; Ricci C; Zamagni C; Nero C; Carbone MV; Ghizzoni V; Sorio R; Salvatore S; Tronconi F; Savarese A; Scambia G; Lorusso D;